Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market
On January 7, Teva Pharmaceuticals and MedinCell announced positive results from their Phase III trial (RISE Study) evaluating mdc-IRM (risperidone)…
API Manufacturers
Latest in
API Manufacturers
Logistics and transport main concern related to clinical trial supply chain: Survey Results
The pharmaceutical supply chains were disrupted due to the Covid-19 pandemic creating a shortage of raw materials and ancillary supplies…
Does Arcturus’ one-shot Covid-19 vaccine have the potential to match up with leading BioNTech/Pfizer and Moderna candidates?
Leading COVID-19 vaccine candidates from Pfizer/BioNTech (BNT-162b2) and Moderna (mRNA-1273) currently in Phase III trials reported greater than 90% efficacy,…
Why a surge in PD-1/PD-L1 targeted combination trials is shaping the future of cancer treatment
Targeting programmed cell death protein and its ligand (PD-1/PD-L1) have become the backbone of immunotherapy for cancer. In an era…
By
Registration of head-to-head psoriatic arthritis clinical trial begins the battle for second place
On 17 November 2020, Novartis registered a Phase III psoriatic arthritis (PsA) clinical trial of its IL-17 inhibitor Cosentyx (secukinumab)…
By
The US States with the Most Covid-19 Cases, Covid-19 Trials, and Disrupted Clinical Trials
As the world continues to fight the COVID-19 pandemic while still trying to find its footing with the economy, the…
By
Could improving clinical trial design result in more drug approvals for Schizophrenia?
On November 11, the FDA published a review of Phase III trials of drugs to treat schizophrenia. The review identified…
By
The increasing influence of industry sponsors along the pandemic timeline
The first quarter of 2020 was a period of uncertainty in the timeline of the COVID-19 pandemic, as the pathogenicity…
By